drugset / Trial / NCT06481189
A Safety, Pharmacokinetics and Pharmacodynamics Study of GNR-086 and Ilaris® in Healthy Volunteers
RandomizedParallel-groupSingle-blindOther
Summary
This is a randomized single-blind comparative parallel group study of the safety, pharmacokinetics and pharmacodynamics of GNR-086 and Ilaris® in healthy volunteers. Participants received a single subcutaneous dose of canakinumab 150 mg. The follow up period was 120 days.
Timeline
- Start
- 2022-09-06
- Primary completion
- 2023-03-17
- Completion
- 2023-05-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Canakinumab | Monoclonal antibody | 150 mg | Subcutaneous |
| Subject | GNR-086 | Unknown | 150 mg | Subcutaneous |
Indications
No indication recorded.